These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16302640)

  • 41. Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis.
    Busca A; Cavecchia I; Locatelli F; D'Ardia S; De Rosa FG; Marmont F; Ciccone G; Baldi I; Serra R; Gaido E; Falda M
    Transpl Infect Dis; 2012 Feb; 14(1):40-8. PubMed ID: 21599817
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [THE SPECIES COMPOSITION OF AGENTS OF COMMUNITY-ACQUIRED INFECTIONS OF URINARY TRACTS AND SENSITIVITY OF MAIN UROPATHOGENS TO ANTIBACTERIAL PREPARATIONS IN MOSCOW IN 2013].
    Filimonova OY; Stolyarova LG; Sidorenko SV; Rott IM; Lysenko TI; Narkhova TV; Dmitrieva VA; Golovenko GI; Vlasova IV; Safonova TB; Taranenko LA
    Klin Lab Diagn; 2015 Oct; 60(10):58-61. PubMed ID: 26841676
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
    Redman R; Damiao R; Kotey P; Kaniga K; Davies T; Naber KG
    J Chemother; 2010 Dec; 22(6):384-91. PubMed ID: 21303745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Distribution and antibiotic resistance of pathogen isolated from mid-stream urine of 658 patients].
    Wu Y; Cai X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Nov; 35(11):1189-95. PubMed ID: 21131743
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Spectrum of pathogens and resistance to antibiotics in urinary tract infections and the consequences for antibiotic treatment: study of urology inpatients with urinary tract infections (1994-2001)].
    Wagenlehner E; Niemetz A; Naber G
    Urologe A; 2003 Jan; 42(1):13-25. PubMed ID: 12574879
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral ofloxacin therapy of infections due to multiply-resistant bacteria.
    Scully BE; Clynes N; Neu HC
    Diagn Microbiol Infect Dis; 1991; 14(5):435-41. PubMed ID: 1797458
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinicomicrobiological characteristics of community-acquired infections of the urinary tracts in Moscow].
    Rafal'skiĭ VV; Rokhlikov IM; Strachunskiĭ LS
    Urologiia; 2007; (5):18, 20-3. PubMed ID: 18254219
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emergence of resistance to fluoroquinolones among gram positive and gram negative clinical isolates.
    Nesar S; Shoaib MH; Rahim N; Rehman R
    Pak J Pharm Sci; 2012 Oct; 25(4):877-81. PubMed ID: 23010009
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment with cedax in asymptomatic bacteriuria in the first trimester of pregnancy].
    Pŭnevska M
    Akush Ginekol (Sofiia); 2001; 40 Suppl 5():26-7. PubMed ID: 11785352
    [No Abstract]   [Full Text] [Related]  

  • 50. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Analysis of the etiologic structure of urinary tract infection and antibiotic-resistance of its pathogens].
    Derevianko II; Khodyreva LA
    Antibiot Khimioter; 1997; 42(9):27-32. PubMed ID: 9412416
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).
    Zhanel GG; Hisanaga TL; Laing NM; DeCorby MR; Nichol KA; Palatnik LP; Johnson J; Noreddin A; Harding GK; Nicolle LE; Hoban DJ;
    Int J Antimicrob Agents; 2005 Nov; 26(5):380-8. PubMed ID: 16243229
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The disturbing development of resistance in urinary tract infections].
    Hampel C; Gillitzer R; Pahernik S; Thüroff JW
    Urologe A; 2003 Jan; 42(1):27-33. PubMed ID: 12574880
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bacterial profile and drug susceptibility pattern of urinary tract infection in pregnant women at Tikur Anbessa Specialized Hospital Addis Ababa, Ethiopia.
    Assefa A; Asrat D; Woldeamanuel Y; G/Hiwot Y; Abdella A; Melesse T
    Ethiop Med J; 2008 Jul; 46(3):227-35. PubMed ID: 19271386
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the antibacterial activity of lomefloxacin with that of other antibiotic/chemotherapeutic agents.
    Cuffini AM; Tullio V; Vaiani G; Carlone NA
    J Chemother; 1989 Jul; 1(4 Suppl):178-81. PubMed ID: 16312358
    [No Abstract]   [Full Text] [Related]  

  • 56. [The use of Maxaquin (lomefloxacin hydrochloride) in the treatment of nonspecific inflammatory diseases and in the prevention of surgical interventions in urology].
    Derevianko II; Lopatkin NA; Khodyreva LA; Kondrat'eva EM
    Urol Nefrol (Mosk); 1998; (5):14-8. PubMed ID: 9820038
    [No Abstract]   [Full Text] [Related]  

  • 57. [Antimicrobial susceptibility of the uropathogens in out patients in Goiânia City, Goiás State].
    Poletto KQ; Reis C
    Rev Soc Bras Med Trop; 2005; 38(5):416-20. PubMed ID: 16172759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cefepime (maxipime) in the treatment of severe urinary tract infection].
    Derevianko II
    Antibiot Khimioter; 2003; 48(7):24-8. PubMed ID: 14628575
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.
    Wagenlehner FM; Alidjanov JF
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):959-66. PubMed ID: 27327964
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changing profile of pediatric community-acquired UTI in a hospital in South India.
    Venkat Ramanan P; Sharma S; Krishna V
    J Trop Pediatr; 2014 Dec; 60(6):483. PubMed ID: 25232152
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.